Gsa Capital Partners LLP Citius Pharmaceuticals, Inc. Transaction History

Gsa Capital Partners LLP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 15, 2023	SELL	$0.65 - $1.25 $114,145 - $219,510	-175,608 Reduced 46.94%	198,492 $134,000
Q2 2023 Aug 14, 2023	SELL	$1.08 - $1.65 $84,737 - $129,460	-78,461 Reduced 17.34%	374,100 $448,000
Q1 2023 May 12, 2023	SELL	$0.78 - $1.42 $36,053 - $65,635	-46,222 Reduced 9.27%	452,561 $529,000
Q4 2022 Feb 13, 2023	BUY	$0.79 - $1.28 $282,326 - $457,440	357,375 Added 252.73%	498,783 $394,000
Q3 2022 Nov 14, 2022	BUY	$0.14 - $1.33 $19,797 - $188,072	141,408 New	141,408 $171,000
Q3 2021 Nov 12, 2021	SELL	$1.74 - $2.6 $77,699 - $116,103	-44,655 Closed	0 $0
Q2 2021 Aug 05, 2021	SELL	$1.51 - $4.23 $19,343 - $54,186	-12,810 Reduced 22.29%	44,655 $155,000
Q1 2021 May 10, 2021	BUY	$1.04 - $2.34 $24,578 - $55,301	23,633 Added 69.85%	57,465 $102,000
Q4 2020 Feb 03, 2021	BUY	$0.9 - $1.2 $30,448 - $40,598	33,832 New	33,832 $35,000

30.6M

24.7K

Ticker CTXR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 146,130,000
Market Cap $65.8M
Description
Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic l...

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Gsa Capital Partners LLP with notifications on news.